2024 Conference
Explore key agenda highlights, top speakers, and industry insights from the 2024 Life Sciences IP Due Diligence Summit.
CONFERENCE CO-CHAIRS
Tom Irving
Partner
The Marbury Law Group, PLLC
Forrester Liddle
Head of Intellectual Property and Legal for US R&D
Novo Nordisk
Develop a new forward thinking, “bespoke” life sciences IP due diligence strategy with insights from a faculty of 40+ leading speakers.
Meet over a dozen inhouse counsel who actively work in the IP due diligence space including lawyers Merck, Johnson & Johnson, Teva Pharmaceuticals, Gilead Sciences, and Zentalis Pharmaceuticals.
Hear first-hand from deal-makers and investors on what they look for when making a deal and what diligence results may hinder investment.
SPECIAL SESSION ON IP DUE DILIGENCE IN THE AGE OF AI WITH
Charles Kim
Deputy Commissioner for Patents
United States Patent and Trademark Office
GAIN INSIGHTS FROM KEY INDUSTRY STAKEHOLDERS INCLUDING
Tashica Williams Amirgholizadeh, Ph.D.
Senior Associate General Counsel, IP,
IP Alliance and Due Diligence (IPADD), Team Lead
Gilead Sciences, Inc.
Anna L. Cocuzzo
Managing Counsel, Patents, Boston
Merck
William Vickery
Director of Due Diligence
Servier
Featured Sessions
IP Policy Deep Dive on how Loper, orange book de-listings, the IRA and potential march-in rights are impacting diligence
Spotlight on Terminal Disclaimers and Double Patenting
Cellect and Xencor problem solving Think Tank
Focus on International Diligence Concerns from the UPC to the BIOSECURE Act
Two Exclusive Roundtables focusing on Dealmaking and Investing
Download 2024 Brochure
Flip through our 2024 conference brochure and discover the hot topics discussed.